Search results
Black Box Warnings. An increase in all-cause mortality has been observed in a meta-analysis of Phase 3 and 4 clinical trials in tigecycline-treated patients versus comparator. Tigecycline should be reserved for use in situations when alternative treatments are not suitable.
Aug 1, 2024 · TYGACIL ®. Active ingredient (s): tigecycline. Consumer Medicine Information (CMI) This leaflet provides important information about using Tygacil. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Tygacil.
Tygacil is FDA-approved to treat complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP).
